PMID- 30181602 OWN - NLM STAT- MEDLINE DCOM- 20200207 LR - 20220416 IS - 1473-1150 (Electronic) IS - 1470-269X (Linking) VI - 19 IP - 3 DP - 2019 Jun TI - BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis. PG - 269-276 LID - 10.1038/s41397-018-0041-5 [doi] AB - Brain-derived neurotrophic factor (BDNF) plays an important role in dopaminergic and serotonergic neurotransmission by modulating dopaminergic neuron differentiation and establishment. Multiple studies have analyzed the functional BDNF Val66Met variant in relation to antipsychotic response in schizophrenia (SCZ) patients, yielding mixed results. A meta-analysis was thus performed to examine the relationship between this variant and symptom improvement during antipsychotic treatment. Searches using PubMed, Web of Science, and PsycInfo until October 2017 yielded 11 studies that met inclusion criteria (total n = 3774). These studies investigated the BDNF Val66Met variant and antipsychotic response in patients with SCZ or schizoaffective disorder. Responders to antipsychotics were defined using the original criteria applied in each study. Effect sizes were computed using odds ratios, which were pooled according to the Mantel-Haenszel method. The BDNF Val66Met variant was not associated with the total number of responders and non-responders (p > 0.05) under dominant, recessive, or allelic models. Secondary analyses stratifying for individuals of each ethnicity and drug type also revealed no significant associations. Our findings suggest that the BDNF Val66Met variant is not associated with response to antipsychotics in individuals with SCZ. However, considering the current sample size, small effects cannot be ruled out. Moreover, recent studies have suggested that Val66Met forms haplotypes with other BDNF variants. Future studies should examine the Val66Met variant in conjunction with these other variants in relation to antipsychotic response. Moreover, since illness duration appears to influence BDNF levels in SCZ patients, future studies should aim to control for this potential confounding factor in response analyses. FAU - Huang, Eric AU - Huang E AD - Psychiatric Neurogenetics Section, Campbell Family Research Institute Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. AD - Institute of Medical Science, University of Toronto, Toronto, ON, Canada. FAU - Hettige, Nuwan C AU - Hettige NC AD - Psychiatric Neurogenetics Section, Campbell Family Research Institute Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. AD - Institute of Medical Science, University of Toronto, Toronto, ON, Canada. FAU - Zai, Gwyneth AU - Zai G AD - Psychiatric Neurogenetics Section, Campbell Family Research Institute Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, ON, Canada. AD - Frederick W. Thompson Anxiety Disorders Centre, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. FAU - Tomasi, Julia AU - Tomasi J AD - Psychiatric Neurogenetics Section, Campbell Family Research Institute Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. AD - Institute of Medical Science, University of Toronto, Toronto, ON, Canada. FAU - Huang, Justin AU - Huang J AD - Psychiatric Neurogenetics Section, Campbell Family Research Institute Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. FAU - Zai, Clement C AU - Zai CC AD - Psychiatric Neurogenetics Section, Campbell Family Research Institute Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, ON, Canada. FAU - Pivac, Nela AU - Pivac N AD - Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia. FAU - Nikolac Perkovic, Matea AU - Nikolac Perkovic M AD - Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia. FAU - Tiwari, Arun K AU - Tiwari AK AD - Psychiatric Neurogenetics Section, Campbell Family Research Institute Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, ON, Canada. FAU - Kennedy, James L AU - Kennedy JL AD - Psychiatric Neurogenetics Section, Campbell Family Research Institute Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. jim.kennedy@camh.ca. AD - Department of Psychiatry, University of Toronto, Toronto, ON, Canada. jim.kennedy@camh.ca. LA - eng GR - CIHR/Canada PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20180905 PL - United States TA - Pharmacogenomics J JT - The pharmacogenomics journal JID - 101083949 RN - 0 (Antipsychotic Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 7171WSG8A2 (BDNF protein, human) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Alleles MH - Antipsychotic Agents/*therapeutic use MH - Brain-Derived Neurotrophic Factor/*genetics MH - Female MH - Genotype MH - Humans MH - Male MH - Middle Aged MH - Polymorphism, Single Nucleotide/*genetics MH - Psychotic Disorders/*drug therapy/*genetics MH - Schizophrenia/*drug therapy/*genetics MH - Young Adult EDAT- 2018/09/06 06:00 MHDA- 2020/02/08 06:00 CRDT- 2018/09/06 06:00 PHST- 2018/01/17 00:00 [received] PHST- 2018/06/19 00:00 [accepted] PHST- 2018/05/01 00:00 [revised] PHST- 2018/09/06 06:00 [pubmed] PHST- 2020/02/08 06:00 [medline] PHST- 2018/09/06 06:00 [entrez] AID - 10.1038/s41397-018-0041-5 [pii] AID - 10.1038/s41397-018-0041-5 [doi] PST - ppublish SO - Pharmacogenomics J. 2019 Jun;19(3):269-276. doi: 10.1038/s41397-018-0041-5. Epub 2018 Sep 5.